Drugs in MeSH Category Nucleic Acid Synthesis Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shorla	JYLAMVO	methotrexate	SOLUTION;ORAL	212479-001	Nov 29, 2022		RX	Yes	Yes	11,771,701		Y
Assertio Speclty	OTREXUP PFS	methotrexate	SOLUTION;SUBCUTANEOUS	204824-014	May 31, 2017		DISCN	Yes	No
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-007	Mar 24, 2016		DISCN	Yes	No	8,021,335		Y
Hikma	DACTINOMYCIN	dactinomycin	INJECTABLE;INJECTION	090304-001	Mar 16, 2010		DISCN	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Nucleic Acid Synthesis Inhibitors

Last updated: April 24, 2026

What drugs define the NLM MeSH scope “Nucleic Acid Synthesis Inhibitors”?

NLM MeSH class “Nucleic Acid Synthesis Inhibitors” captures small molecules and related therapeutics that inhibit pathways required for DNA and RNA synthesis. In practice, the class clusters into target modalities that recur across major therapeutic areas: thymidylate synthesis, purine synthesis, pyrimidine synthesis, thymidine phosphorylation, and direct enzyme inhibition at nucleic acid replication steps.

Market relevance is strongest for oncology and antiviral segments, where nucleotide synthesis and salvage pathways are rate-limiting for proliferating cells or viral replication. The patent landscape is dominated by:

• First-in-class enzyme inhibitors (historically: antimetabolites)
• Second-generation potency, selectivity, and safety improvements
• Prodrugs and delivery systems that change exposure-time profiles
• Combination regimens that protect lifecycle through new claims

Practical mapping used for market and patent scanning (not exhaustive):

• Antimetabolites (e.g., thymidylate synthase inhibitors, antifolates, antipurines)
• Nucleoside/nucleotide analogs used as incorporation inhibitors
• Host/viral nucleic acid replication enzyme inhibitors (where classification is applied broadly by indexing)

How do market dynamics shape demand in this class?

1) Oncology drives base consumption; antivirals drive episodic surges

Demand is most consistent in oncology because proliferative tumor biology creates high dependency on nucleotide biosynthesis and salvage. Antivirals show:

• Clear epidemic or guideline-driven procurement cycles
• Rapid shift in preferred mechanisms as resistance patterns evolve

2) Payor behavior rewards oral dosing and predictable toxicity

Across major geographies, formularies increasingly favor:

• Oral regimens with stable administration
• Lower-grade toxicity that reduces dose interruption and monitoring burden
• Predictable pharmacokinetics that support fixed dosing

These preferences influence patentable activity around:

• Prodrug conversion profiles
• Formulation and solubility
• Dosing schedule claims tied to clinical endpoints

3) Resistance and combination strategy widen the lifecycle window

Resistance in nucleotide metabolism or incorporation pathways forces:

• Combination strategies
• Schedule changes (sequence-dependent synergy)
• Use in biomarker-defined subpopulations

From a patent standpoint, companies protect value by claiming:

• Specific combination pairings
• Specific lines of therapy
• Biomarker-enriched populations, where allowed by jurisdiction

4) Biosafety and manufacturing complexity are not uniform

While many “nucleic acid synthesis inhibitors” are small molecules, portions of the class include analogs and specialty chemistries. This creates different execution risks:

• Generic entry can be rapid for early antimetabolites once protection ends
• But complex analog syntheses can slow follow-on entrants

5) Generic and biosimilar competitive intensity is high at the end of molecule exclusivity

Antimetabolites often face:

• Early generic competition once patent bundles expire
• Me-too improvements that compete on tolerability rather than mechanism

The result is that the most durable revenue in the class typically comes from late-lifecycle differentiation:

• Targeting resistance mechanisms
• New formulations
• Patent-protected dosing regimens

---

Who are the patent-active players in nucleic-acid-synthesis inhibition?

Patent activity concentrates in large pharma and specialty oncology companies. The most consistent pattern across the class is broad coverage by:

• Original developers protecting core composition of matter and method-of-use
• Lifecycle managers filing continuation families for narrower claims tied to patient subgroups and combinations
• Generic challengers filing for market entry upon expiry of key patents

Because MeSH indexing does not uniquely map to a single ATC group or mechanism category, companies with heavy oncology or antiviral footprints dominate the patent count.

---

What does the patent landscape look like by protection layer?

1) Composition of matter (MoC) is the anchor

For most drugs in the class, the initial patent term extension value sits in:

• New active compounds
• Salts, hydrates, and polymorphs (where new)
• Novel stereochemistry or regioisomer definitions

2) Method-of-use claims carry the second wave

Companies often shift from broad oncology indication claims into:

• Specific cancer subtypes
• Specific lines of therapy
• Combination therapy claims

These claims help manage:

• Competitive erosion from generics
• Indication expansion that can preserve market exclusivity in new segments

3) Formulation and prodrug claims are common lifecycle levers

A frequent strategy is protecting improvements that change:

• Absorption and exposure
• Intracellular activation kinetics (for prodrugs and nucleoside analogs)
• Tolerability via controlled release or optimized salt forms

4) Dosage regimen and schedule claims

Schedule claims become relevant when clinical benefit depends on exposure timing:

• Cyclic dosing
• Sequential administration with partner therapies
• Loading-dose approaches

5) New resistance-directed claims

As resistance mechanisms emerge, filings increasingly specify:

• Use with companion therapies designed to overcome resistance
• Biomarker-directed selections

---

Where are the main patent “pressure points” for investors?

1) Patent bundle fragility near expiry

The value of this class is often concentrated in:

• A small number of key patents per molecule (MoC + core method-of-use)
• Dependent claims with narrower therapeutic coverage

When these core patents lapse, generic penetration accelerates unless:

• A later-expiring patent remains enforceable
• A formulation or regimen patent blocks substitution

2) Jurisdictional variability in patent term management

Exclusivity depends on:

• Patent term adjustment and extension mechanics
• Regulatory exclusivity awards (where applicable)
• Claim construction outcomes in litigation

This drives uneven market protection across major markets.

3) Combination claims face enforcement complexity

Even if a combination regimen is patented, practical enforcement can be limited by:

• Prescriber preference patterns
• Real-world adoption of off-label combinations
• Formulary substitution dynamics

---

How does patent strategy differ between oncology and antivirals?

Oncology

Patent strategy emphasizes:

• Patient selection
• Line-of-therapy claims
• Combination regimens and schedule optimization
• Safety and dosing reduction claims

Lifecycle is often maintained via multiple overlapping secondary patents.

Antivirals

Patent strategy emphasizes:

• Resistance-informed use
• Viral genotype or phenotype subgroups
• Combination therapies that reduce resistance escape

Given rapid guideline shifts, early patent families often carry disproportionate value.

---

What are the commercialization bottlenecks that affect uptake and litigation risk?

1) Safety constraints and dose-limiting toxicities

Where toxicity is a primary barrier, the patent landscape can include:

• Reduced dose regimen claims
• Supportive care regimen claims (where patentable)
• Formulation upgrades to reduce peak exposure

2) Biomarker test availability

Biomarker-directed method-of-use claims depend on practical testing. If tests are not widely adopted, enforcement and real-world prescribing can be constrained.

3) Generic substitution rules

Even with a protected formulation or schedule, substitution rules vary by market and can reduce enforceability.

---

Where does the class sit relative to other nucleic-acid pathway categories?

For market sizing and competitive positioning, investors typically triangulate MeSH “nucleic acid synthesis inhibitors” against neighboring categories:

• Antineoplastic agents
• Antimetabolites and folate pathway drugs
• Antiviral nucleoside analogs
• DNA synthesis and replication inhibitors

Cross-indexing is essential because patents are filed around mechanisms and targets more precisely than MeSH indexing.

---

Patent landscape implications for R&D portfolio decisions

Target selection

Companies that have sustained patent estates typically align to targets with:

• High pathway dependency in defined populations
• Resistance mechanisms that can be countered with follow-on compounds or combinations

Claim architecture

High-value portfolios often show:

• Strong MoC claims
• Broad but defensible method-of-use claims
• Secondary patents that cover:
  • dosing schedules
  • formulations
  • combinations

Lifecycle sequencing

Best-performing strategies in this class typically file and prosecute:

• First compound families early
• Continuations that broaden or narrow claims based on clinical data
• Formulation and prodrug families after PK and tolerability signals

---

Key Takeaways

• The MeSH class “Nucleic Acid Synthesis Inhibitors” maps in practice to oncology antimetabolites and antiviral nucleic-acid pathway inhibitors; oncology drives stable baseline demand, antivirals drive episodic spikes.
• Patent value is structured across composition of matter, method-of-use, formulation/prodrug, and schedule/combination claims; lifecycle durability depends on how many of these remain enforceable when core patents expire.
• Combination and regimen patents often provide meaningful protection but carry enforcement complexity; investors should model real-world substitution and off-label prescribing risk.
• The dominant pressure points are bundle expiry timing, jurisdictional term management, and claim dependency fragility.

---

FAQs

1) Are nucleic acid synthesis inhibitors mostly antimetabolites or do they include nucleoside analogs?

They include both. MeSH indexing captures drugs that inhibit nucleic-acid synthesis broadly, which in commercial practice spans classical antimetabolites and nucleoside/nucleotide analog incorporation inhibitors.

2) What type of patent claim most often preserves exclusivity for this class?

Exclusivity often persists through a layered portfolio: MoC plus method-of-use, with formulation/prodrug and dosing regimen or combination claims as the second wave.

3) Why do combination regimens matter for patent strategy?

Because they extend value after core MoC expiry by creating method-of-use exclusivity tied to clinical pairing and treatment setting, even when alternative monotherapies enter.

4) What erodes revenue the fastest in this category?

Generic substitution after the expiration of key MoC and core method-of-use patents, especially when late-lifecycle differentiation (formulation or regimen) is not strongly enforceable or not widely adopted.

5) How do resistance dynamics change the patent landscape?

Resistance can shift standard-of-care toward combination approaches and biomarker-guided selection, which drives follow-on patents and continuation filings focused on resistant subpopulations and regimen tailoring.

---

References

[1] National Library of Medicine. MeSH Browser. “Nucleic Acid Synthesis Inhibitors.” https://meshb.nlm.nih.gov/